Retatrutide

Retatrutide research peptide primarily functions as a unimolecular triple agonist, binding with tailored potency to GLP-1 receptors (favoring cAMP signaling for insulin secretion and satiety), GIP receptors (enhanced potency for improved insulin dynamics and lipid metabolism), and glucagon receptors (attenuated activation to boost energy expenditure and hepatic lipid oxidation). Furthermore, it promotes glucose-dependent insulin release from beta cells, suppresses glucagon in a context-sensitive manner, delays gastric emptying, and centrally influences hypothalamic regions to reduce food intake while peripherally increasing thermogenesis and fatty acid utilization. Additionally, laboratory models reveal synergistic effects on mitochondrial function, reduced inflammation, and superior weight regulation compared to dual agonists, with structural insights from cryo-EM confirming balanced receptor engagement. These integrated actions contribute to observed improvements in models of hyperglycemia, obesity, and steatotic liver disease, with recent research underscoring its reassuring profile for multifaceted metabolic pathway activation and enhanced homeostasis.

• Triple incretin receptor (GLP-1/GIP/glucagon) activation investigations

• Glucose homeostasis and insulin secretion mechanism analysis

• Appetite suppression and energy expenditure studies

• Hepatic lipid metabolism and steatotic liver evaluations

• Weight regulation and body composition pathway research

• Cardiometabolic and anti-inflammatory effects examinations in metabolic models

• Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526
• Rosenstock J et al. Lancet. 2023;402(10401):529-544
• Malik ME et al. Diabetes Obes Metab. 2023;25(9):2416-2428
• Urva S et al. Cell Metab. 2022;34(6):903-914
• Coskun T et al. Mol Metab. 2022;60:101489